Login to Your Account

Clinic Roundup

Monday, November 12, 2012

• Biotron Ltd., of Sydney, Australia, started a Phase II trial with its lead antiviral drug candidate, BIT225 in patients that are co-infected with both HIV and hepatitis C virus (HCV).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription